We Serve

Financial Services

Discover how our data-driven solutions have helped stakeholders in Precision Medicine drive growth and stay ahead of the curve

What we do

Select Capabilities

All Capabilities

Revenue Projection

No one can predict the future, but with the right research and analysis, you can understand the different market scenarios you may face. DeciBio takes a data-driven approach, considering customer demand and preference, product profile, competitive dynamics, regulation, and other market factors to inform your potential revenue scenarios.

Data Analytics

Use it or lose it. If you’re not leveraging your data to extract insights on your customers and market, you’re falling behind. We’re here to help with bespoke data services.

Biomarker and Diagnostics Strategy

This is where precision medicine starts – whether you’re trying to find the right tools to uncover new biomarkers, identify CDx partners, launch an IVD, or understand how your assay will fit into the clinical journey, DeciBio has you covered. Nobody knows biomarkers and CDx better than DeciBio.

Impact

Selected Work

Financial Services

CDD on Novel Handheld Diagnostic Device Manufacturer

A global healthcare investment firm wanted to perform a commercial due diligence (CDD) prior to investment in a company producing a novel handheld diagnostic.

Voice-of-Customer Research

KOL Identification

Pricing Strategy

Revenue Projection

Due Diligence

Featured Team

Stephane Budel

Founding Partner

David Cavanaugh

Founding Partner

Andrew Aijian

Miguel Edwards

Carl Schoellhammer

Data & Platforms

Pharma Real-Word Data & Evidence Market Report, First Edition: 2025-2030

The first edition of this report provides a comprehensive overview of the global real-world data and evidence (RWD/E) market from 2025 to 2030. RWD has become increasingly central in life sciences decision-making, empowering organizations to generate insights that enhance research, clinical development, and commercial decision-making. The market is expanding as data types diversify, spanning electronic health records, claims, imaging, and omics, and as analytics become more advanced through AI and federated data approaches. Key players include data aggregators, generators (e.g., Guardant Health, Natera), enablers (e.g., COTA, Aetion), as well as players that span multiple functions (e.g., Tempus, Flatiron, NashBio).

Global In Vitro Diagnostics Market Report, First Edition: 2025-2030

DeciBio’s Global In Vitro Diagnostics Market Report, First Edition: 2025-2030, is an in-depth, data-driven resource designed to support strategic decision-making in the IVD space. This report provides a summary of the current IVD landscape, as well as a forward-looking perspective of the IVD market from 2025 to 2030. Content includes a rigorous assessment of industry market size, growth and key trends. In addition, we provide detailed segmentation by modality, therapeutic area, and geography.

Proteomics Tools Report: Research & Clinical Markets, First Edition: 2025-2030

The first edition of this report provides a comprehensive overview of the global proteomics tools market from 2025 to 2030. These tools are fundamental to life sciences, enabling the analysis of proteins, the functional endpoints of biological pathways. The landscape is highly dynamic, with a clear duality: established, first-generation tools (e.g., IHC, ELISAs, Western blot) remain critical in clinical trials and routine diagnostics, while a high-growth research segment is driven by innovative technologies like high-plex affinity platforms and spatial proteomics. The vendor landscape includes large corporations such as Thermo Fisher Scientific and Roche, as well as specialized innovators like Olink, SomaLogic, and Quantum-Si.

Analytical Instrument Utilization Report

This report provides a summary of historical (2019-2025) and expected (2025-2027) analytical instrument use across academic core laboratories in the U.S., Europe, and APAC.

Insights Blog

Precision Medicine is evolving at a rapid pace

Discover how we can help